CAROL MILLER: Open Payments
NPI 1306535927 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$525 in 16 payments from 7 companies in 2025. Trend: 2023 $502 · 2024 $588 · 2025 $525
Food & beverage: $525
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $189 |
| GENZYME CORPORATION | 2 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Adaptive Biotechnologies Corporation | 1 | $32 |
| BeOne Medicines USA, Inc. | 1 | $29 |
| Celgene Corporation | 1 | $22 |
| Legend Biotech USA Inc. | 1 | $21 |
Products named: SARCLISA, CARVYKTI, TECVAYLI, NINLARO, clonoSEQ, TALVEY, BRUKINSA, ABECMA.
Industry payments across TX — which companies pay providers there.
